SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1599075
This article is part of the Research TopicDeciphering the Inflammatory Response in Colorectal and Ovarian CancersView all 3 articles
Prognostic significance of the pretreatment pan-immune-inflammation value in colorectal cancer patients: An updated meta-analysis
Provisionally accepted
- Cancer Hospital, Chongqing University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The prognostic importance of the pretreatment pan-immuneinflammation value (PIV) in colorectal cancer has been extensively documented, yet its role remains unclear. This study aims to conduct an updated meta-analysis to elucidateing the relationship between the pretreatment PIV and long-term survival outcomes among patients diagnosed with colorectal cancer.Methods: A systematic literature review was performed in PubMed, Embase, Web of Science and CNKI to identify eligible studies from inception to January 18, 2025. The primary endpoints evaluated were survival outcomes. Hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs) for survival outcomes were extracted. A random-effects model was utilized to synthesize the findings. All statistical analyses were conducted using R software, version 4.2.1.Out of 81 identified studies, a total of 14 retrospective studies including 6,192 colorectal cancer patients were ultimately included. In this meta-analysis, the pooled results demonstrated that patients with higher PIV exhibited significantly poorer overall survival (11 studies, HR=1.95; 95%CI:1.64-2.31; P<0.01; I 2 = 34%) and diseasefree survival (10 studies, HR= 1.89; 95% CI: 1.48-2.41; P < 0.01; I 2 = 66%). Furthermore, evidence pooled from two studies demonstrated that PIV may be an independent prognostic factor for cancer-specific survival (HR= 2.61; 95% CI: 1.56-4.38; P < 0.01; I 2 = 0%).Our study reveals that the pretreatment PIV can serve as a valuable biomarker for predicting long-term survival outcomes in patients with colorectal 3 cancer, which may have important clinical implications for personalized treatment strategies.
Keywords: colorectal cancer, Pan-Immune-Inflammation Value, overall survival, Disease-Free Survival, Cancer-specific survival, Meta-analysis
Received: 27 Mar 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Li, Pang, Sun and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hao Sun, Cancer Hospital, Chongqing University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.